Alpha 2.0
Login Register
» Authors » Joseph Aumann

Joseph Aumann

Explore the profile of Joseph Aumann including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 96
Followers 0
Related Specialties
Pulmonary Medicine
Critical Care
Top 10 Co-Authors
Maria Gabrovska
Vincent Ninane
Thierry Troosters
Geert M Verleden
Hans Slabbynck
Kris Bogaerts
Wim Janssens
Kristina Vermeersch
Guy G Brusselle
Ingel K Demedts
Published In
Int J Chron Obstruct Pulmon Dis
Pulm Pharmacol Ther
Respir Res
J Inflamm Res
Am J Respir Crit Care Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Monomeric CRP is Elevated in Patients with COPD Compared to Non-COPD Control Persons
Munuswamy R, De Brandt J, Burtin C, Derave W, Aumann J, Spruit M, et al.
J Inflamm Res . 2021 Sep; 14:4503-4507. PMID: 34522118
Chronic low-grade systemic inflammation is frequently observed in patients with chronic obstructive pulmonary disease (COPD), e.g., elevated pentameric CRP (pCRP). However, pCRP can dissociate to form monomeric CRP (mCRP) which...
2.
Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo - a post-hoc analysis of the BACE randomized controlled trial
Vermeersch K, Belmans A, Bogaerts K, Gyselinck I, Cardinaels N, Gabrovska M, et al.
Respir Res . 2019 Oct; 20(1):237. PMID: 31665017
Background: In the BACE trial, a 3-month (3 m) intervention with azithromycin, initiated at the onset of an infectious COPD exacerbation requiring hospitalization, decreased the rate of a first treatment...
3.
Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial
Vermeersch K, Gabrovska M, Aumann J, Demedts I, Corhay J, Marchand E, et al.
Am J Respir Crit Care Med . 2019 May; 200(7):857-868. PMID: 31046405
Azithromycin prevents acute exacerbations of chronic obstructive pulmonary disease (AECOPDs); however, its value in the treatment of an AECOPD requiring hospitalization remains to be defined. We investigated whether a 3-month...
4.
The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
Vermeersch K, Gabrovska M, Deslypere G, Demedts I, Slabbynck H, Aumann J, et al.
Int J Chron Obstruct Pulmon Dis . 2016 Apr; 11:687-96. PMID: 27099485
Background: Long-term use of macrolide antibiotics is effective to prevent exacerbations in chronic obstructive pulmonary disease (COPD). As risks and side effects of long-term intervention outweigh the benefits in the...
5.
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P
Int J Chron Obstruct Pulmon Dis . 2014 Mar; 9:215-28. PMID: 24596459
Background: Addition of a second bronchodilator from a different pharmacological class may benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) whose symptoms are insufficiently controlled by bronchodilator monotherapy. GLOW6...
6.
Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study
LaForce C, Aumann J, de Teresa Parreno L, Iqbal A, Young D, Owen R, et al.
Pulm Pharmacol Ther . 2010 Jul; 24(1):162-8. PMID: 20619353
Purpose: Indacaterol is a novel, once daily, inhaled ultra-long-acting β₂-agonist for the treatment of chronic obstructive pulmonary disease (COPD). Here we compared the 24-h spirometry profile of once daily indacaterol...